Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onyx gains on Nexavar revenues

ONXX gained $8.68 (18%) to $58.03 on Wednesday after the company reported late Tuesday that it swung to a

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE